Clinical trials: Allogeneic Stem-Cell Transplant
Hematologic Malignancies, Nonmalignant Diseases
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Melphalan is a chemotherapy drug used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of melphalan in their bodies and if drug…
- Conditions
- Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies
- Trial name
- NCT03609827
- Testing
- Melphalan
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Lymphoma, Follicular, Stem Cell Transplantation
Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
This trial will evaluate the efficacy and the safety of a strategy of allogeneic stem cell transplantation including Rituximab in the conditioning regimen for the treatment of relapsed follicular lymphoma.
- Trial name
- RITALLO (NCT01208896)
- Testing
- Reduced_intensity conditioning
- Where
- 26 sites in France
- Volunteers
- 32 people
- Sponsor
- University Hospital, Bordeaux
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Current protocols use G-CSF to mobilize hematopoietic progenitor cells from matched sibling and volunteer unrelated donors. Unfortunately, this process requires four to six days of G-CSF injection and can be associated with side…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma
- Trial name
- NCT02639559
- Testing
- BL-8040, Leukapheresis, Hematopoietic cell transplant
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Lymphoma
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
The goal of this clinical research study is to study the safety of ADCETRISTM (brentuximab vedotin) in patients with Hodgkin lymphoma or ALCL who have had an allogeneic or haploidentical stem cell transplant.
- Trial name
- NCT02169505
- Testing
- Brentuximab Vedotin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Graft Versus Host Disease
Photopheresis for the Treatment of Acute Graft Versus Host Disease
The goal of this clinical research study is to find out whether adding extracorporeal photopheresis (ECP) to standard therapy for acute GVHD with corticosteroids improves response to treatment, length of treatment, and survival.
- Trial name
- NCT00609609
- Testing
- Photopheresis, Methylprednisolone
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- M.D. Anderson Cancer Center
T Cell Lymphoma
Allo-HSCT as First-line Consolidation in High-risk PTCL
Results of conventional therapy in patients with peripheral T-cell lymphoma(PTCL) are poor. Allogeneic hematopoietic stem cell transplantation(allo-HSCT) gave excellent results in PTCL after failure of conventional therapy and in…
- Trial name
- NCT03672084
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Myelodysplastic Syndromes
BMS-986253 in Myelodysplastic Syndromes
Background: The myelodysplastic syndromes (MDS) are a group of bone marrow neoplasms. MDS mostly affect elderly people. The drugs used to treat MDS are not always effective, and the only curative treatment is stem cell…
- Trial name
- NCT05148234
- Testing
- Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Liver Failure
Safety and Efficacy of Diverse Mesenchymal Stem Cells Transplantation for Liver Failure
HBV-related liver failure (HBV-LF), a dramatic clinical syndrome, is characterized with massive necrosis of liver cells. Liver transplantation might be the most effective therapy for HBV-LF.
- Trial name
- NCT01844063
- Testing
- Conventional plus BM-MSC treatment, Conventional plus UC-MSC treatment, Conventional treatment
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Myelodysplastic Syndrome
Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation
The purpose of this study is to evaluate the feasibility and efficacy of reduced-intensity conditioning allogeneic HCT followed by prophylactic dose-escalating DLIs in patients with higher risk MDS.
- Trial name
- RICandDLI (NCT01252784)
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Cooperative Study Group A for Hematology
Hodgkin Lymphoma, Lymphocytic Leukemia
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
Background: Allogeneic blood and marrow stem cell transplantation (BMT) plays an important role in the curative treatment of a number of pediatric malignancies.
- Conditions
- Hodgkin Lymphoma, Lymphocytic Leukemia, Mixed Cell Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00013533
- Testing
- Stem cell transplantation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Neoplasm
Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS
Use of magrolimab in combination with standard intensive chemotherapy ("7+3" or CPX-351) in newly diagnosed "ELN 2022 intermediate or adverse-risk" AML or high risk MDS patients, who intend to undergo allogeneic stem cell…
- Trial name
- MAGROLIC (NCT05829434)
- Testing
- Magrolimab, 7+3, CPX-351
- Sponsor
- Uwe Platzbecker
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia
Patients with acute leukaemia requiring induction or consolidation chemotherapy and those requiring a haematopoietic stem cell transplant are at high risk of fever and infection when they have low white cell counts (neutropenic…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Haematopoietic Stem Cell Transplant, Autologous, Haematopoietic Stem Cell Transplant, Allogeneic
- Trial name
- PIPPIN (NCT03429387)
- Testing
- FDG-PET/CT, Conventional CT
- Where
- 2 sites in Australia
- Volunteers
- 147 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Electric Stimulation Therapy
Safety and Feasibility of Electrical Muscle Stimulation During Stem Cell Transplantation or Intensive Chemotherapy
Intensive chemotherapy, with or without following autologous or allogeneic stem cell transplantation (HSCT), is often the only curative treatment option for patients with haematological malignancies, leave many survivors…
- Trial name
- NCT03467087
- Testing
- Myopuls 2000D
- Volunteers
- 45 people
- Sponsor
- University Hospital, Saarland
Infection
Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation
RATIONALE: Antivirals such as valganciclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valganciclovir is effective in preventing cytomegalovirus.
- Trial name
- NCT00016068
- Testing
- ganciclovir, valganciclovir
- Where
- 7 sites in United States
- Volunteers
- 184 people
- Sponsor
- Fred Hutchinson Cancer Center
AML, MDS
Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)
The purpose of this study is to evaluate the OS, RFS, and TRM after HCT with low-dose total body irradiation, fludarabine, and busulfan conditioning.
- Conditions
- AML, MDS, ALL, CML
- Trial name
- NCT00815568
- Testing
- fludarabine phosphate, busulfan
- Where
- South Korea
- Volunteers
- 114 people
- Sponsor
- Samsung Medical Center
HIV-1-infection
Analytical Treatment Interruption in a Patient With HIV Post Allogeneic Stem Cell Transplantation From a CCR5 delta32 Homozygous Donor
Patients who have Human Immunodeficiency Virus-1 (HIV-1) infection, who also had a stem cell transplant may have achieved cure of their HIV infection.
- Trial name
- ATI (NCT06582797)
- Testing
- discontinuation of ART
- Volunteers
- 10 people
- Sponsor
- University of Kansas Medical Center
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
This research is a phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational intervention to learn whether it works in treating a specific cancer.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01643668
- Testing
- Busulfan, Clofarabine, Allogeneic Stem Cell Infusion
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Graft-Versus-Host-Disease
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis
IL-2 add-back post allogeneic hematopoietic stem cell transplant (HSCT), combined with Sirolimus (SIR), Tacrolimus (TAC) will optimize Treg reconstitution and prevent graft versus host disease (GVHD).
- Trial name
- NCT01927120
- Testing
- IL-2, Tacrolimus, Sirolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Adenovirus Infection
Clinical Grade Adenovirus Specific T Cells for Immunotherapy After Allogeneic Stem Cell Transplantation (CTL-ADV)
Fourteen patients will be included for infusion of adenovirus-specific T-cells generated by a clinical grade IFN-γ based immunomagnetic isolation from a leukapheresis from their original donor or a haploidentical donor, in case…
- Trial name
- CTL-ADV (NCT02851576)
- Testing
- Infusion of ADV specific T cells
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Central Hospital, Nancy, France
Acute Myeloid Leukemia
Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial
To better delineate the contribution of VEN-DEC to the treatment of AML patients aged between ≥ 60 and < 75 years and deemed fit for Allo-HSCT, real-world data on a patient-level basis will be collected and utilized to generate a…
- Trial name
- VenDec-AI (NCT07420790)
- Where
- Italy
- Volunteers
- 1,941 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.